secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lipocine Inc. (LPCN)
CIK:        0001535955
Form:       8-K
Filed at:   2025-08-05T23:59:59+00:00
Accession:  0001493152-25-011589
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lipocine Q2 net loss narrows to $2.2M; Phase 3 PPD study underway
-----------------------------------------------------------------

- Net loss of $2.2M ($0.41/diluted share) vs $3.1M loss year ago; cash $17.9M at quarter end.
- LPCN 1154 Phase 3 pivotal trial for postpartum depression dosing patients; topline Q2 2026, NDA mid-2026.
- LPCN 2401 Phase 2 proof-of-concept study in obesity planned, first patient dosing target Q3 2025.
- TLANDO NDS filed in Canada by Verity Pharma in June; Brazil license deal with Aché in April.
- Total revenue $623K (Q2) vs $90K year ago, including $500K license revenue.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1535955/000149315225011589/0001493152-25-011589-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1535955/000149315225011589/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-011589

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer